Marta Outón
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Marta Outón has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Blanco-Sánchez
Department of Hematology and Hemotherapy, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
1 shared publication - Cristina Agulló
Department of Clinical Biochemistry and Laboratory Medicine, Hospital Universitario de Salamanca, 37007 Salamanca, Spain
1 shared publication - Daniel Gil-Alós
Hospital 12 de Octubre, Madrid, Spain
1 shared publication - Elena Ana López-Jiménez
Department of Clinical Biochemistry and Laboratory Medicine, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
1 shared publication - Fátima Miras
Department of Hematology and Hemotherapy, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
1 shared publication - Joaquín Martínez-López
Department of Hematology and Hemotherapy, Hospital Universitario 12 de Octubre, 28041 Madrid, Spain
1 shared publication
Latest Publications
- Open Access
- 28 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 2933
Mass Spectrometry Profiling of Therapeutic Antibodies in Multiple Myeloma: m/z Features and Concordance with Immunofixation Electrophoresis
Background/Objectives: Therapeutic monoclonal antibodies, including bispecifics (t-mAbs), can interfere with serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE), mimicking residual M-protein. We evaluated a mass spectrometry (MS; EXENT®)-based workflow supported by an m/z reference library to discriminate drug from disease and assess concordance with IFE. Methods: Fifty-eight serum samples from 29 multiple myeloma patients were analyzed at baseline and after 3 months. Targeted enrichment of t-mAbs followed by MS enabled detection of peaks annotated through matching to a theoretical m/z panel and correlation with SPEP/IFE results. Results: Comparison of IFE versus MS showed 11/29 (38%) double positives, 15/29 (52%) double negatives, and 3/29 (10%) IFE−/MS+; no IFE+/MS− cases were observed. Using MS as a reference, IFE exhibited 78.6% sensitivity and 100% specificity. The m/z library enabled attribution of interference to linvoseltamab (n = 9), daratumumab (n = 6), and teclistamab (n = 3); in 16 patients treated with other bispecifics, no drug-related peaks were detected after 3 months. Longitudinal analysis discriminated therapeutic from endogenous immunoglobulins, identified baseline M-protein, and prevented false residual signals. Conclusions: MS (EXENT®)-based characterization of t-mAbs improves response monitoring accuracy in multiple myeloma and supports integration of MS into routine laboratory practice.
- 28 November 2025
- Published by MDPI AG in Biomedicines
- Vol. 13 (12) , 2933
Open AccessMass Spectrometry Profiling of Therapeutic Antibodies in Multiple Myeloma: m/z Features and Concordance with Immunofixation Electrophoresis
Background/Objectives: Therapeutic monoclonal antibodies, including bispecifics (t-mAbs), can interfere with serum protein electrophoresis (SPEP) and immunofixation electrophoresis (IFE), mimicking residual M-protein. We evaluated a mass spectrometry (MS; EXENT®)-based workflow supported by an m/z reference library to discriminate drug from disease and assess concordance with IFE. Methods: Fifty-eight serum samples from 29 multiple myeloma patients were analyzed at baseline and after 3 months. Targeted enrichment of t-mAbs followed by MS enabled detection of peaks annotated through matching to a theoretical m/z panel and correlation with SPEP/IFE results. Results: Comparison of IFE versus MS showed 11/29 (38%) double positives, 15/29 (52%) double negatives, and 3/29 (10%) IFE−/MS+; no IFE+/MS− cases were observed. Using MS as a reference, IFE exhibited 78.6% sensitivity and 100% specificity. The m/z library enabled attribution of interference to linvoseltamab (n = 9), daratumumab (n = 6), and teclistamab (n = 3); in 16 patients treated with other bispecifics, no drug-related peaks were detected after 3 months. Longitudinal analysis discriminated therapeutic from endogenous immunoglobulins, identified baseline M-protein, and prevented false residual signals. Conclusions: MS (EXENT®)-based characterization of t-mAbs improves response monitoring accuracy in multiple myeloma and supports integration of MS into routine laboratory practice.